Marsh & McLennan (MMC) CEO trades options and sells 16,656 shares

Rhea-AI Filing Summary

Marsh & McLennan Companies President and CEO John Q. Doyle reported an option exercise and related share sale. He exercised options to acquire 16,656 shares of Common Stock at $73.195 per share, then sold 16,656 shares at $161.71 per share in an open‑market transaction.

The filing notes that the sale was effected under a pre‑arranged Rule 10b5‑1 trading plan, meaning it was scheduled in advance. After these transactions, Doyle continues to hold over 100,000 shares of Marsh & McLennan stock directly.

Insider Trade Summary 10b5-1

Net Seller: 16,656 shares ($2,693,442)

Net Sell 3 txns

Insider Doyle John Q

Role President and CEO

Sold 16,656 shs ($2.69M)

Type	Security	Shares	Price	Value
Exercise	Stock Options (Right to Buy)	16,656	$0.00	--
Exercise	Common Stock	16,656	$73.195	$1.22M
Sale	Common Stock	16,656	$161.71	$2.69M

Holdings After Transaction: Stock Options (Right to Buy) — 33,312 shares (Direct, null); Common Stock — 133,467.021 shares (Direct, null)

Footnotes (1)

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. These options were granted on February 22, 2017 and vested in four equal annual installments on February 22nd of 2018, 2019, 2020 and 2021.

Key Figures

Shares sold: 16,656 shares Sale price: $161.71 per share Options exercised: 16,656 shares +3 more

6 metrics

Shares sold 16,656 shares Common Stock sold at $161.71 per share on June 2, 2026

Sale price $161.71 per share Open-market sale of Marsh & McLennan Common Stock

Options exercised 16,656 shares Common shares acquired via option exercise on June 2, 2026

Exercise price $73.195 per share Stock options (Right to Buy) for Marsh & McLennan Common Stock

Remaining stock options 33,312 options Stock Options (Right to Buy) outstanding after exercise, expiring February 21, 2027

Net share direction 16,656 net shares sold transactionSummary netBuySellShares with net-sell direction

Key Terms

Rule 10b5-1 trading plan, Stock Options (Right to Buy), exercise or conversion of derivative security, open-market sale

4 terms

Rule 10b5-1 trading plan regulatory

"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Stock Options (Right to Buy) financial

"Stock Options (Right to Buy) with an exercise price of $73.195 per share"

exercise or conversion of derivative security financial

"transaction code description: Exercise or conversion of derivative security"

open-market sale financial

"transaction_action: open-market sale of Common Stock"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Doyle John Q

(Last) (First) (Middle)

1166 AVENUE OF THE AMERICAS

(Street)

NEW YORK NEW YORK 10036

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MARSH & MCLENNAN COMPANIES, INC. [ MRSH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/02/2026		M(1)		16,656	A	$73.195	133,467.0205	D
Common Stock	06/02/2026		S(1)		16,656	D	$161.71	116,811.0205	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$73.195	06/02/2026		M(1)			16,656	(2)	02/21/2027	Common Stock	16,656	$0	33,312	D

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

2. These options were granted on February 22, 2017 and vested in four equal annual installments on February 22nd of 2018, 2019, 2020 and 2021.

	/s/ Tessa Patti, Attorney-in-fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Marsh & McLennan (MMC) CEO John Doyle report?

John Doyle reported an option exercise and a share sale. He exercised options to acquire 16,656 Marsh & McLennan common shares at $73.195, then sold 16,656 shares at $161.71 per share as part of a disclosed insider trading plan.

How many Marsh & McLennan (MMC) shares did the CEO sell and at what price?

The CEO sold 16,656 Marsh & McLennan shares at $161.71 each. The transaction is classified as an open‑market or private sale, reported as a non‑derivative disposition of common stock on the same date as the related option exercise.

What stock options did the Marsh & McLennan (MMC) CEO exercise in this Form 4?

Doyle exercised stock options for 16,656 common shares at $73.195. These options were originally granted on February 22, 2017 and vested in four equal annual installments from 2018 through 2021, according to the filing’s footnote disclosures.

Was the Marsh & McLennan (MMC) CEO’s share sale under a Rule 10b5-1 plan?

Yes. The CEO’s sale was executed under a Rule 10b5‑1 trading plan. A footnote states the transaction was effected pursuant to a previously adopted plan, indicating the trade was pre‑scheduled rather than a discretionary, ad‑hoc sale.

How many Marsh & McLennan (MMC) shares does CEO John Doyle still hold after these transactions?

The filing shows Doyle continues to hold more than 100,000 shares. Reported post‑transaction ownership figures for his direct common stock position exceed this level, even after the exercise‑and‑sell sequence disclosed in the Form 4.

What derivative holdings related to Marsh & McLennan (MMC) stock remain after the CEO’s option exercise?

The derivative table shows 33,312 stock options remaining after the exercise. These options carry a $73.195 exercise price, relate to 33,312 underlying common shares, and have an expiration date of February 21, 2027 as disclosed.